David is the founder and Chief Executive Officer of SHEPHERD and the Executive Director of the SHEPHERD Foundation. He is a Forbes 30 Under 30 honoree and Spotlight Health Scholar at the Aspen Institute. David previously founded an NGO that worked with refugee children, worked as an undercover investigator against the sexual enslavement of children in Southeast Asia, and was in the training pipeline for Special Operations in the U.S. Military until he was diagnosed with Adenoid Cystic Carcinoma in 2015. David combined the fearlessness, determination and desire to save the lives of others that had marked his previous endeavors to found SHEPHERD with one goal in mind – to save the life of every rare cancer patient. David holds a B.A. in Economics, Philosophy and French Literature from Transylvania University, a M.A.L.A. in Intellectual History from St. John’s College, a M.Div from Harvard University in Religion, Ethics & Politics, and is currently completing his Executive MBA through the Owner/President Management Program at Harvard Business School.
A different type of company and person
Gene Williams is the Executive Chairman of ProMIS Neurosciences, a publicly traded biotech focused on therapy development for Alzheimer’s disease. As former Senior Vice President of Program and Portfolio Management at Genzyme, Gene comes to SHEPHERD with expert knowledge on commercialization integration, drug development, and deal making. Prior to his time at Genzyme, Williams worked as a consultant at Bain & Company and Corporate Decisions Inc., where he served as co-Head of Healthcare focused on commercialization strategies and on speeding and improving the drug development process. Gene most recently co-founded and acted as CEO of Dart Therapeutics, an orphan disease drug development company determined to improve clinical trial efficiency and maximize investor resources. Eugene holds a B.A. from Harvard University and an M.B.A. from Harvard Business School.
Gene is an avid guitar player, biker, and gourmet cook although usually not at the same time.
Timothy G. Rothwell is currently the Chairman of Emisphere Technologies Inc. (OTC: EMIS), a commercial stage, specialty pharmaceutical company since early 2012 and prior to that a Director of the Company from late 2009. Mr. Rothwell is also the Chairman of Speracura LLC, a healthcare consulting company from 2009 and the President of the SDHB PHEOPARA Coalition from 2016.
Mr. Rothwell was formerly Chairman of Sanofi from February 2007 to October 2009 in the U.S. He also served as Chief Executive Officer and President of Sanofi-Aventis from September 2004 to February 2007. Mr. Rothwell oversaw all domestic commercial operations as well as the coordination of Industrial Affairs and Research and Development activities in the U.S. From May 2003 to September 2004, Mr. Rothwell was President and Chief Executive Officer of Sanofi-Synthelabo, Inc. and was instrumental in the formation of Sanofi-Aventis U.S. in 2004. Prior to that, from January 1998 to May 2003, he served in various capacities at Pharmacia, including as President of the company’s Global Prescription Business. From January 1995 to January 1998, Mr. Rothwell also served as worldwide President of Rhone-Poulenc Rorer Pharmaceuticals and President of the company’s Global Pharmaceutical Operations. In his long career, Mr. Rothwell has also served as Chief Executive Officer of Sandoz Pharmaceuticals, Vice President of Global Marketing and Sales at Burroughs Wellcome, and Senior Vice President of Marketing and Sales for the U.S. for Squibb Corporation which later became a Division of Bristol-Myers Squibb.
Mr. Rothwell holds a Bachelor of Arts from Drew University and earned his J.D. from Seton Hall University.
He formerly served on the PhRMA Board of Directors, as well as the Institute of Medicine’s Evidence-Based Medicine roundtable, the CEO Roundtable on Cancer, the Healthcare Businesswoman’s Association Advisory Board, the Board of Trustees for the Somerset Medical Center Foundation, the Board of Trustees for the HealthCare Institute of New Jersey, as a Trustee of the Corporate Council for America’s Children at the Children’s Health Fund, the Board of Directors of Agenus (NASDAQ: AGEN), the Board of Directors of Akrimax Pharmaceuticals LLC, Chairman of the Board of Directors of Archimedes Pharma LLC , Chairman of the Board of Directors of New American Therapeutics, and a member of the Board of Visitors for Seton Hall Law school.
He also served as the Chairman of the Pheo Para Alliance from 2009 to 2014 which is a non-profit organization dedicated to helping patients who suffer from pheochromocytoma and paraganglioma.
Dr. Kaplan comes to SHEPHERD from Genzyme, where she served as Vice President of Research. Over the course of her 24-year career in biotechnology, Johanne directed pioneering research and partnerships leading to the implementation of multiple clinical trials in the fields of gene therapy, autoimmunity, and oncology. She led the scientific research support of several approved drugs in the oncology space including alemtuzumab, clofarabine, and plerixafor. Prior to joining Genzyme, Johanne was an Associate Immunopathologist at SmithKline Beecham where she established an immunotoxicology program. Her work has resulted in over 60 scientific publications and multiple patents. Johanne holds a B.Sc. and a Ph.D. in Microbiology & Immunology from McGill University in Montreal, Canada and conducted post-doctoral studies at the Albert Einstein College of Medicine in New York.
Johanne is a life-long scientist, who values critical thinking and efficiency. Her most efficient day to date: she had a job interview in the morning and went into labor in the afternoon. A brand new baby boy and a new job the next day!
Dr. Siders received his B.Sc. Degree in 1990 from the University of North Carolina at Pembroke and his Ph.D.degree in 1995 from the Department of Microbiology and Immunology at Wake Forest University. He trained as a post-doctoral fellow at both the National Cancer Institute and at MethylGene in the area of gene therapy and cancer. He joined Genzyme in 1998 and was involved in evaluating several immunotherapy candidates in pre-clinical cancer models using both viral and non-viral platforms. Work during his tenure involved identifying and developing therapeutics for both cancer and autoimmune disease. Most recently, Dr. Siders became responsible for leading the Neuroimmunology Research Group focusing on the identification and validation of therapeutic targets for multiple sclerosis. He has been involved with several development programs including alemtuzumab where he participated in the FDA Advisory Committee meeting and regulatory filings. In July of 2017, Dr. Siders joined SHEPHERD Therapeutics as Chief Development Officer to lead the validation and development of novel therapies for the treatment of rare cancers.
Shabnam joins SHEPHERD as Chief Business Officer by way of Otsuka Pharmaceuticals, Sanofi, and Bristol-Meyers-Squibb. She has dedicated her career to oncology patients and has expertise in licensing, business development, oncology commercial strategy, and oncology product launch.
Shabnam joined Otsuka in 2009 and has held a number of leadership positions there, focusing on the company’s entry into oncology, a co-promotion alliance, and the acquisition of Astex Pharmaceuticals.
Before joining Otsuka, Kazmi was VP, licensing and business development, at Sanofi U.S. and earlier worked at Bristol-Myers Squibb in global and U.S. marketing and lifecycle management.
Kazmi has received numerous awards and has held leadership roles on the boards of a number of organizations. She received an A.B. degree in biochemistry and economics at Smith College and an M.B.A. from Harvard Business School.
Dr. Barber is a graduate of the Biological and Biomedical Sciences Ph.D. program with a degree in cellular biology. Her thesis studies in the Cell Biology Department were conducted in Dr. John Blenis’s laboratory, which has contributed to delineating aberrant signaling pathways in oncogenesis. Jamie studied the mTOR signaling pathway and alternative splicing regulation, as well as characterizing additional phosphorylation events downstream of the AGC kinases. Before her graduate studies, Jamie spent two years as a post-baccalaureate fellow at the National Cancer Institute, where she studied in Dr. Jonathan Wiest’s laboratory focusing on the proto-oncogene MAP3K8. Following the completion of her Ph.D. studies, Jamie spent time as the head teaching fellow for both molecular and cellular biology courses at Harvard University, as well as instructor of “The Biology of Cancer” course at Harvard Extension School. Her expertise covers cancer-related molecular and cellular mechanisms, with particular interest in intracellular signaling pathways aberrantly activated during oncogenesis. Jamie holds a B.S. from Austin Peay State University and a Ph.D in cell biology from Harvard University.
Our Jamie brings smiles to people’s faces with her trained therapy dog, Scraps, and grows tomatoes in her backyard garden while raising her infant son.
Kate comes to SHEPHERD with an unusual story. Her first career was in small press publishing, where she ran two literary magazines and a small press that published work from and interviews with from Nobel and Pulitzer Prize winners — before the age of 22. That work made her realize the power of design and technology to drive innovation and develop new realities about what business can be. For the next ten years, she ran an independent design and development firm that contracted with clients that varied from small businesses and startups to major corporations including Fidelity, RE/MAX, and Jackson Hewitt.
In 2010, looking for a new perspective, Kate began her studies at Harvard University Extension school. While working full time, she served for over two years as a Harvard research assistant, ultimately earning an ALB degree with a concentration in economics and minors in quantitative analysis and government. While at Harvard, Kate discovered her love for a new type of “design” — statistics and data analysis.
In 2015, she and her co-founder launched a startup, eventually backed by the Harvard Innovation Lab, that used wearable devices and data analytics to predict and prevent burnout in nurses — a $2 billion problem. But in late 2016, Kate‘s fiancé was diagnosed with oligodendroglioma, a rare brain cancer whose standard of care includes the use of chemotherapies more than 40 years old. She quickly refocused on SHEPHERD’s mission.
In her current role, Kate uses her experience as a developer, technologist, and budding analyst to search for, organize, and assess research. The common themes in her work are a passion for entrepreneurship, a drive to adopt new technologies for uncommon purposes, and a love for taking dozens of seemingly disconnected threads and weaving them into new solutions — whether it’s a new application, a new company, or a new opportunity for SHEPHERD.
She is a native of Norfolk, Virginia and was not keen on writing her bio.
Lauren joins the SHEPHERD team as Vice President of Operations. She has worked in the financial industry in Manhattan for over a decade, including completing the Sales & Trading training program at JP Morgan Chase and acquiring her Series 7 and 63 licenses. Lauren has worked in sales and trading, hedge funds and private equity in compliance, investor relations and financial operations roles. She also worked in the defense industry for two years at a technology-focused defense contractor in Washington D.C. She is a summa cum laude graduate of Wake Forest University.
Lauren is drawn to the mission to leave no cancer patient without hope. She also finds it invigorating to be a Yankee fan at a Boston-based company.
Dr. Mahta Samizadeh is a pharmaceutical scientist and pharmacist, with nearly ten years of experience in designing polymeric drug delivery systems and performing physicochemical, biological and efficacy characterization, and expertise in mucosal immunity and inflammation. Before joining Shepherd Therapeutics, she was a postdoctoral fellow at Tufts University. Her expertise lies in designing polymeric nanocarriers for targeted delivery of small molecule drugs as well as mapping pathways associated with mucosal immunity and inflammation.
Dr. Samizadeh’s former areas of experience include the intense study of anti-inflammatory gene and protein expression in acute and chronic mouse models of Chaga’s disease. She also assisted with drug/target development for mouse models of Sjögren’s disease, in collaboration with Biogen as well as with the Forsyth Institute on phase 1 clinical trial sample processes and analysis to study the pattern of changes in saliva in patients with Sjögren’s syndrome.
Dr. Samizadeh received her PhD. in Pharmaceutical Sciences from Rutgers University.
Dr. Rupaimoole is a graduate of the Biomedical Sciences Ph.D program, majoring in Cancer biology and Cell biology from the Graduate School of Biomedical Sciences, University of Texas – MD Anderson Cancer Center at Houston. His research during Ph.D. focused on elucidating the role of hypoxia-mediated miRNA biogenesis deregulation in cancer growth and metastasis. He identified key regulatory pathways effecting miRNA biogenesis under hypoxia exposure in tumors. He has developed therapeutic methods to target these aberrations using DOPC encapsulated siRNAs or miRNAs. Upon completion of Ph.D, he moved to Dr. Frank Slack lab, based in Harvard Medical School/Beth Israel Deaconess Medical Center , to carry out his postdoctoral studies. During his tenure at Dr. Slack lab, he identified small molecules to combine synergistically with miRNA mimics as therapeutics against lung cancer.
Rajesha is a native of the southern Indian coastal city of Mangalore and likes to explore different cuisines, cultures, with a passion for travel.
Debashree Chakrabarti graduated with a Masters in Biotechnology from D.Y Patil University (Mumbai) & Masters in Biological Sciences from University of Massachusetts, Lowell (UML).
As a research assistant in UML, she studied the involvement of the Sonic Hedgehog pathway in jaw size regulation and its implications in congenital craniofacial anomalies. Her thesis in India focused on identifying chromosomal aberrations in children diagnosed with autistic disorder by means of karyotyping peripheral blood lymphocytes.
Prior to her engagement with Shepherd Therapeutics, Debashree supported the Genome Technologies group in Abbvie profiling gene expressions for various autoimmune biomarkers and thereafter worked with the Data Informatics team in automating MSD analysis.
Yuhan comes to SHEPHERD from Boston Children’s Hospital and Dr. Langer’s Lab at the Koch Institute for Integrated Cancer Research at MIT. She completed her B.A. in Analytical Chemistry in Shanghai at the East China University of Science and Technology, then her Master’s in Chemistry at NYU. With Dr. Langer, Yuhan helped develop polymer-encapsulated beta cells for long-term glycemic control as a cure for Type 1 Diabetes. At NYU, Yuhan helped develop the lead product for what became the medical device company – SensoDx – a microfluidic beads-based immunoassay platform for early detection of Myocardial Infarction Disease. Ms. Zhu also worked in the Physics Department at NYU, working to develop programmable single-stranded DNA Coated TMP Microspheres , and in the Department of Analytical Chemistry at ECUST to develop novel nanoparticle-activated SERS.
SHEPHERD welcomes Louie, a scholar of applied mathematics and computation. His work entails researching and developing modern methods behind drug combination and synergy, as well as engineering novel machine learning methods for SHEPHERD’s proprietary discovery engine. His specific areas of interest include Volterra and Fredholm integral equations for the study of predator-prey population dynamic models, as well as oncological game theory and methods within mathematical biology.
Louie graduated magna cum laude from Spring Hill College, a small Jesuit college in Mobile, Alabama, where he was captain of the varsity track and field team, as well as an academic and athletic scholar.
Louie recently hiked 442 miles across the north of Spain on El Camino de Santiago. By virtue of his Louisiana roots, he likes to cook, but
enjoys eating more. Louie looks forward to attaining his PhD in biomedical engineering.
Kara Knappe joins the SHEPHERD team as the Assistant to the CEO. Kara comes to SHEPHERD by way of southern California where she spent much of her youth focused on the theater. After years of performing, she moved to NYC where she quickly discovered that she preferred eating and paying rent to auditioning and being rejected so she took a position as a personal assistant to an art collector and philanthropist. After living in New York for 12 years, she decided she’d like to move closer to her parents who retired in Kentucky and chose to call Nashville home. Here, she continued working in a private household as an assistant for a year and half before accepting a position as the Assistant to the President of the Nashville Health Care Council where she worked for just over 2 years.
Kara brings close to 15 years of personal and executive assistant experience to the position and is looking forward to supporting David and the SHEPHERD team as they continue to move their mission forward.
Elle Ross serves as Government Relations Counsel at SHEPHERD. She also concurrently serves as legislative counsel and Manager of Army Programs at the National Guard Association advocating for operational reserve forces. Prior to coming to Capitol Hill, Ross worked on veterans issues at a local law firm. On the hill, Ross has worked for Rep. Peter King, NY-02, and the office of Rep. Pete Sessions, TX-32. She served Sessions, the chairman of the Rules Committee, as legislative counsel and handled the legislative portfolios on military, defense and healthcare. Ross earned a Master of Laws Degree (LL.M) in national security and U.S. foreign relations law from George Washington University Law before starting her career in Washington, D.C. She has also previously worked at Harris Corporation in the government relations division in addition to her time at the McChrystal Group LLC consulting firm. She earned her Juris Doctorate Degree (J.D.) from New England School of Law, Boston in 2012.
Ross is a licensed attorney in the District of Columbia and judge advocate in the Army Reserves.